Raisio prepares financial review 2005
Life Sciences business area sees increase in turnover.
13/02/06 Rasion saw a slight drop in operating result, excluding one-off items, over the previous year, as it prepared the company’s financial review for 2005.
- Turnover for 2005 was nearly the same as the previous year: EUR 434.6 million (EUR 437.9 million in continuing operations in 2004).
- Operating result, excluding one-off items, amounted to EUR 9.1 million (EUR 10.6 million in continuing operations, excluding one-off items in 2004). The recorded operating result in the financial statements was EUR -10.9 million (EUR -18.4 million).
- Earnings per share, excluding one-off items, was EUR 0.05 (EUR 0.07). Reported earnings per share amounted to EUR -0.04 (EUR -0.12). The Board of Directors proposes a dividend of EUR 0.05 per share.
- Raisio’s renewal started with increased product development inputs, investments and networking.
- Operating result for 2006 is expected to improve over the previous year.
Turnover in the Raisio Life Sciences business area increased by 10.7%, amounting to EUR 59.0 million (EUR 53.3 million) thanks to the good development seen in the ingredients business. Turnover from the diagnostics business also grew slightly over the previous year.
Profitability improved and the operating result, excluding one-off items, amounted to EUR 7.5 million (EUR 4.4 million). The result was boosted by the continued growth in ingredients sales during 2005. The development of markets for sterol-based ingredients has enabled Raisio to gain a strong foothold on the markets with its Benecol ingredient and to put its skills to wider use throughout the production chain for sterol-based ingredients. The diagnostics business focused on enhancing operations and renewing the product portfolio. Significant inputs made in product development pushed the result of the diagnostics business into the red.
Raisio Life Sciences recorded an operating result of EUR 2.4 million (EUR -4.8 million), which included a write-down of EUR 5.1 million on the goodwill of the diagnostics business.
